• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

While C-Cure had failed an essential phase 3 clinical trial in June last year, the trial identified a subgroup of patients where the drug was effective nonetheless. Based on this fact, C-Cure now receives Fast Track designation from the US drug policy maker.

Biocartis has revealed its pick for its vacant top function.

Galapagos and development partner Gilead set out to explore filgotinib applicability even futher. This time, the molecule's anti-inflammatory capacity will be tested in cutaneous lupus erythematosus.

Kiadis Pharma asks permission to the EMA to bring its lead product to the market. ATIR101™ protects blood cancer patients receiving a stem cell transplant from vulnerability to infections and disease relapse.

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

While C-Cure had failed an essential phase 3 clinical trial in June last year, the trial identified a subgroup of patients where the drug was effective nonetheless. Based on this fact, C-Cure now receives Fast Track designation from the US drug policy maker.

Biocartis has revealed its pick for its vacant top function.

Galapagos and development partner Gilead set out to explore filgotinib applicability even futher. This time, the molecule's anti-inflammatory capacity will be tested in cutaneous lupus erythematosus.

Kiadis Pharma asks permission to the EMA to bring its lead product to the market. ATIR101™ protects blood cancer patients receiving a stem cell transplant from vulnerability to infections and disease relapse.